Alexandra C Hristov

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3274934/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	GATA-3 expression identifies a high-risk subset of PTCL, NOS with distinct molecular and clinical features. Blood, 2014, 123, 3007-3015.	0.6	158
2	HMGA2 Participates in Transformation in Human Lung Cancer. Molecular Cancer Research, 2008, 6, 743-750.	1.5	116
3	HMGA2 protein expression correlates with lymph node metastasis and increased tumor grade in pancreatic ductal adenocarcinoma. Modern Pathology, 2009, 22, 43-49.	2.9	96
4	A novel recurrent NPM1-TYK2 gene fusion in cutaneous CD30-positive lymphoproliferative disorders. Blood, 2014, 124, 3768-3771.	0.6	90
5	Ovarian Metastases of Appendiceal Tumors With Goblet Cell Carcinoidlike and Signet Ring Cell Patterns. American Journal of Surgical Pathology, 2007, 31, 1502-1511.	2.1	83
6	Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2019, 94, 1027-1041.	2.0	77
7	HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Modern Pathology, 2010, 23, 98-104.	2.9	75
8	Optical Coherence Tomography of Cavernous Nerves: A Step Toward Real-Time Intraoperative Imaging During Nerve-Sparing Radical Prostatectomy. Urology, 2008, 72, 198-204.	0.5	68
9	Simplified Flow Cytometric Assessment in Mycosis Fungoides and Sézary Syndrome. American Journal of Clinical Pathology, 2011, 136, 944-953.	0.4	60
10	Comparative analysis of rosacea and cutaneous lupus erythematosus: Histopathologic features, T-cell subsets, and plasmacytoid dendritic cells. Journal of the American Academy of Dermatology, 2014, 71, 100-107.	0.6	51
11	T-cell Receptor Signaling Activates an ITK/NF-κB/GATA-3 axis in T-cell Lymphomas Facilitating Resistance to Chemotherapy. Clinical Cancer Research, 2017, 23, 2506-2515.	3.2	49
12	A retrospective comparative outcome analysis following systemic therapy in <scp>M</scp> ycosis fungoides and <scp>S</scp> ezary syndrome. American Journal of Hematology, 2016, 91, E491-E495.	2.0	41
13	Localized cutaneous argyria. Journal of the American Academy of Dermatology, 2011, 65, 660-661.	0.6	33
14	Selected Inflammatory Imitators of Mycosis Fungoides: Histologic Features and Utility of Ancillary Studies. Archives of Pathology and Laboratory Medicine, 2014, 138, 1319-1327.	1.2	28
15	Utility of <scp>CD</scp> 123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T cell lymphoma. Histopathology, 2019, 74, 908-916.	1.6	28
16	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: Diagnostic Considerations. Archives of Pathology and Laboratory Medicine, 2012, 136, 876-881.	1.2	27
17	<i>HMGA1</i> overexpression correlates with relapse in childhood B-lineage acute lymphoblastic leukemia. Leukemia and Lymphoma, 2013, 54, 2565-2567.	0.6	27
18	Bordetella hinzii septicemia in association with Epstein–Barr virus viremia and an Epstein–Barr virus-associated diffuse large B-cell lymphoma. Diagnostic Microbiology and Infectious Disease, 2008, 61, 484-486.	0.8	23

Alexandra C Hristov

#	Article	IF	CITATIONS
19	Controversies and Considerations in the Diagnosis of Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2014, 138, 1307-1318.	1.2	23
20	Primary Cutaneous Follicle Center Lymphoma. Archives of Pathology and Laboratory Medicine, 2018, 142, 1313-1321.	1.2	23
21	Inactivation of the <i>Cdkn2a</i> locus cooperates with <i>HMGA1</i> to drive T-cell leukemogenesis. Leukemia and Lymphoma, 2013, 54, 1762-1768.	0.6	22
22	Mycosis fungoides with <scp>CD20</scp> expression: report of two cases and review of the literature. Journal of Cutaneous Pathology, 2014, 41, 494-503.	0.7	22
23	A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral Tâ€cell lymphomas. American Journal of Hematology, 2017, 92, 1287-1294.	2.0	21
24	Cutaneous Bâ€cell lymphomas: 2021 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2020, 95, 1209-1213.	2.0	21
25	Cutaneous Tâ€cell lymphomas: 2021 update on diagnosis, riskâ€stratification, and management. American Journal of Hematology, 2021, 96, 1313-1328.	2.0	21
26	Extranodal Rosai–Dorfman disease involving the heart: report of two cases. Cardiovascular Pathology, 2010, 19, 380-384.	0.7	19
27	Primary Cutaneous Acral CD8+ T-Cell Lymphoma. Archives of Pathology and Laboratory Medicine, 2017, 141, 1469-1475.	1.2	16
28	Molecular testing of borderline cutaneous melanocytic lesions: SNP array is more sensitive and specific than FISH. Human Pathology, 2019, 86, 115-123.	1.1	16
29	DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach. Modern Pathology, 2020, 33, 1307-1317.	2.9	16
30	Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas. Oncotarget, 2017, 8, 114474-114480.	0.8	15
31	Subcutaneous Panniculitis-Like T-Cell Lymphoma With Bone Marrow Involvement. American Journal of Clinical Pathology, 2015, 143, 265-273.	0.4	14
32	Acute treatment of generalized pustular psoriasis of von Zumbusch with single-dose infliximab. Journal of the American Academy of Dermatology, 2013, 68, e187-e189.	0.6	12
33	Kappa and lambda immunohistochemistry and in situ hybridization in the evaluation of atypical cutaneous lymphoid infiltrates. Journal of Cutaneous Pathology, 2020, 47, 1103-1110.	0.7	12
34	An acneiform eruption secondary to iododerma. JAAD Case Reports, 2018, 4, 468-470.	0.4	11
35	Auer rod–like inclusions in a low-grade B-cell leukemia. Annals of Diagnostic Pathology, 2010, 14, 292-295.	0.6	10
36	Activating mutations of the oncogene EZH2 in cutaneous melanoma revealed by next generation sequencing. Human Pathology: Case Reports, 2014, 1, 21-28.	0.2	10

Alexandra C Hristov

#	Article	IF	CITATIONS
37	Protein gene product 9.5 (PGP9.5) expression in benign cutaneous mesenchymal, histiocytic, and melanocytic lesions: comparison with cellular neurothekeoma. Pathology, 2017, 49, 44-49.	0.3	10
38	A "High-Risk―Epithelioid Hemangioendothelioma Presenting as a Solitary, Ulcerated, Subcutaneous Tumor. American Journal of Dermatopathology, 2011, 33, e88-e90.	0.3	7
39	Primary Cutaneous Composite Lymphomas. Archives of Pathology and Laboratory Medicine, 2018, 142, 1352-1357.	1.2	7
40	Immunophenotypic switch in cutaneous Tâ€cell lymphoma: A series of three cases and review of the literature. Journal of Cutaneous Pathology, 2021, 48, 986-994.	0.7	7
41	Pemphigus herpetiformis: Report of a rare case. Journal of the American Academy of Dermatology, 2012, 67, e231-e233.	0.6	6
42	Case series of volar juvenile xanthogranuloma: Clinical observation of a peripheral rim of hyperkeratosis. Journal of Dermatology, 2014, 41, 933-936.	0.6	5
43	Merkel cell carcinoma arising in association with cutaneous Tâ€cell lymphoma: A potential diagnostic pitfall. Journal of Cutaneous Pathology, 2019, 46, 199-203.	0.7	5
44	Î ³ δ lymphomatoid papulosis type D: A histologic mimic of primary cutaneous Î ³ δ T-cell lymphoma. JAAD Case Reports, 2019, 5, 264-266.	0.4	5
45	Appropriate use criteria for ancillary diagnostic testing in dermatopathology: New recommendations for 11 tests and 220 clinical scenarios from the American Society of Dermatopathology Appropriate Use Criteria Committee. Journal of Cutaneous Pathology, 2022, 49, 231-245.	0.7	5
46	Patch/plaque mycosisâ€fungoidesâ€like presentations of <i><scp>DUSP22</scp>â€</i> translocated Tâ€cell lymphomas. Journal of Cutaneous Pathology, 2022, 49, 299-305.	0.7	5
47	Urticaria multiforme-like eruption due to a novel agent elexacaftor/tezacaftor/ivacaftor in a pediatric patient with cystic fibrosis. JAAD Case Reports, 2021, 18, 71-73.	0.4	5
48	Histopathologic features of Rothmund-Thomson syndrome. JAAD Case Reports, 2019, 5, 726-728.	0.4	4
49	Distinguishing reactive inflammatory dermatoses from lymphoma: 2 cases of severe drug reactions to phenytoin/phenobarbital and rosuvastatin mimicking lymphoma. JAAD Case Reports, 2020, 6, 311-315.	0.4	4
50	Cytogenetic characterization of natural killer cell leukemia. Cancer Genetics and Cytogenetics, 2008, 183, 125-130.	1.0	2
51	Chemotherapy-refractory cutaneous Langerhans cell histiocytosis treated with radiotherapy. Practical Radiation Oncology, 2011, 1, 204-207.	1.1	2
52	Multiple myeloma presenting as cryoglobulinemic vasculitis. JAAD Case Reports, 2021, 11, 81-83.	0.4	2
53	Primary cutaneous follicle center lymphoma with extensive plasmacytic differentiation and t(14;18) in both the lymphoid and plasma cell components. Journal of Cutaneous Pathology, 2021, 48, 969-974.	0.7	1
54	Response to Berry etÂal's "Cutaneous small-vessel vasculitis following single-dose Janssen Ad26.COV2.S vaccination― JAAD Case Reports, 2022, 29, 62-63.	0.4	1

#	Article	IF	CITATIONS
55	Unsuspected lymphomatoid granulomatosis in a patient with antisynthetase syndrome. Cutis, 2017, 100, E22-E26.	0.4	1
56	A diagnosis of mycosis fungoides in a pediatric patient with recurrent Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2018, 65, e26835.	0.8	0
57	Cutaneous follicle center lymphomas with plasmacytic differentiation. Journal of Cutaneous Pathology, 2021, 48, 632-636.	0.7	0